SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

A live webcast will feature SCYNEXIS leaders on Nov. 9

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis

SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

SCYNEXIS will present a candidate that may act against drug-resistant fungi

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator

Scynexis stock surges on $214M BARDA contract for SCY-247

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

SCYX Forecast — Price Target — Prediction for 2027